RU2689977C2 - Применение эрибулина для лечения рака молочной железы - Google Patents

Применение эрибулина для лечения рака молочной железы Download PDF

Info

Publication number
RU2689977C2
RU2689977C2 RU2015126539A RU2015126539A RU2689977C2 RU 2689977 C2 RU2689977 C2 RU 2689977C2 RU 2015126539 A RU2015126539 A RU 2015126539A RU 2015126539 A RU2015126539 A RU 2015126539A RU 2689977 C2 RU2689977 C2 RU 2689977C2
Authority
RU
Russia
Prior art keywords
breast cancer
eribulin
individual
her2
treatment
Prior art date
Application number
RU2015126539A
Other languages
English (en)
Russian (ru)
Other versions
RU2015126539A (ru
Inventor
Олтон КРЕМЕР
Питер ТАРАССОФФ
Мартин ОЛИВО
И. Хэ
Д. Мэттью ГО
Клаудио САВУЛСКИЙ
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50031376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2689977(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of RU2015126539A publication Critical patent/RU2015126539A/ru
Application granted granted Critical
Publication of RU2689977C2 publication Critical patent/RU2689977C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2015126539A 2012-12-04 2013-12-04 Применение эрибулина для лечения рака молочной железы RU2689977C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261733238P 2012-12-04 2012-12-04
US61/733,238 2012-12-04
US201361878204P 2013-09-16 2013-09-16
US61/878,204 2013-09-16
PCT/IB2013/002911 WO2014087230A1 (en) 2012-12-04 2013-12-04 Use of eribulin in the treatment of breast cancer

Publications (2)

Publication Number Publication Date
RU2015126539A RU2015126539A (ru) 2017-01-13
RU2689977C2 true RU2689977C2 (ru) 2019-05-30

Family

ID=50031376

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015126539A RU2689977C2 (ru) 2012-12-04 2013-12-04 Применение эрибулина для лечения рака молочной железы

Country Status (11)

Country Link
US (1) US20140163095A1 (cg-RX-API-DMAC7.html)
EP (1) EP2928464A1 (cg-RX-API-DMAC7.html)
JP (2) JP6466339B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150090921A (cg-RX-API-DMAC7.html)
AU (2) AU2013353745A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015012731A2 (cg-RX-API-DMAC7.html)
CA (1) CA2892780A1 (cg-RX-API-DMAC7.html)
IL (1) IL239007B (cg-RX-API-DMAC7.html)
MX (1) MX2015007185A (cg-RX-API-DMAC7.html)
RU (1) RU2689977C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014087230A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101434673B1 (ko) 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 b 유사체의 제조를 위한 중간체
PE20120923A1 (es) 2009-03-30 2012-08-27 Eisai Randd Man Co Ltd Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013353745A1 (en) * 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
JP6644479B2 (ja) * 2014-06-24 2020-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリンとs−1(もしくは5−fu)の使用
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
MX386547B (es) * 2015-03-04 2025-03-19 Merck Sharp & Dohme Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
UA126029C2 (uk) * 2017-02-20 2022-08-03 Поліфор Аґ Фармацевтичні комбінації для лікування раку
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
EP3654967A4 (en) * 2017-07-21 2021-04-21 Eisai R&D Management Co., Ltd. USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER
EP3713565A1 (en) * 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
BR112020015909A2 (pt) * 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
CN112262157A (zh) * 2018-03-09 2021-01-22 加利福尼亚大学董事会 化药抗性癌症的组合治疗
CN113271977A (zh) * 2018-11-09 2021-08-17 G1治疗公司 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案
ES3075649T3 (en) 2019-07-26 2026-08-06 Eisai R&D Man Co Ltd Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448697C2 (ru) * 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам
RU2452482C2 (ru) * 2005-02-18 2012-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Комбинация и способы введения терапевтических средств и комбинированной терапии

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632433C (en) 1998-06-17 2012-02-07 Eisai R & D Management Co., Ltd. Methods for preparing macrocyclic analogs and intermediates for preparing same
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
KR101434673B1 (ko) 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 b 유사체의 제조를 위한 중간체
EP2578576B9 (en) 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermediates for the synthesis of halichondrin B analogs
RU2517167C2 (ru) 2008-04-04 2014-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аналоги галихондрина в
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
EP2686441B1 (en) * 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
AU2013353745A1 (en) * 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2452482C2 (ru) * 2005-02-18 2012-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Комбинация и способы введения терапевтических средств и комбинированной терапии
RU2448697C2 (ru) * 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDRE F. et al. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann.Oncol. 2012 Aug; 23 Suppl 6: iv46-51 [он лайн] [найдено 13.11.2017] (найдено из интернет: www.ncbi.nlm.nih.gov/pubmed/23012302). HE J. et al. Clinical efficacy of local targereted chemotherapy for triple-negative breast cancer. Rariol.Oncol. 2011 Jun; 45(2): 123-8 Реферат [он лайн] [найдено 13.11.2017] (найдено из интернет: www.ncbi.nlm.nih.gov/pubmed/22933945). MARQUETTE C. et al. Chemotherapy-resistant metastatic breast cancer. Curr.Trat.Options Oncol. 2012 Jun; 13(2): 263-75 Реферат [он лайн] [найдено 13.11.2017] (найдено из интернет: www.ncbi.nlm.nih.gov/pubmed/22528367). DEVRIESE LA et al. Pharmacokinetics of eribuline mesylate in patients with solid tumours receiving repeated oral rifampicin. Br.J.Clin.Pharmacol. 2013 Feb; 75(2): 507-15 [он лайн] [найдено 13.11.2017] (найдено из интернет: www.ncbi.nlm.nih.gov/pubmed/22803519). *

Also Published As

Publication number Publication date
IL239007A0 (en) 2015-07-30
KR20150090921A (ko) 2015-08-06
MX2015007185A (es) 2017-09-05
EP2928464A1 (en) 2015-10-14
RU2015126539A (ru) 2017-01-13
JP6466339B2 (ja) 2019-02-06
JP2016501213A (ja) 2016-01-18
IL239007B (en) 2018-04-30
US20140163095A1 (en) 2014-06-12
BR112015012731A2 (pt) 2017-07-11
AU2018214086A1 (en) 2018-08-23
CA2892780A1 (en) 2014-06-12
AU2018214086B2 (en) 2020-07-09
AU2013353745A1 (en) 2015-06-11
JP2019089776A (ja) 2019-06-13
WO2014087230A1 (en) 2014-06-12
JP6678783B2 (ja) 2020-04-08

Similar Documents

Publication Publication Date Title
AU2018214086B2 (en) Use of eribulin in the treatment of breast cancer
Wang et al. Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Sahin et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18. 2-positive gastric and gastro-oesophageal adenocarcinoma
Saxena et al. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective
Pérez-García et al. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
WO2018234879A1 (en) USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
JP2022082565A (ja) がんを処置するための方法
JP6695003B2 (ja) 癌のための併用療法
EA030664B1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
AU2011338383A1 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
US20200405719A1 (en) Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
JP2020514281A (ja) 進行したher2発現がんの治療
CN113164415A (zh) 依拉司群和阿贝西利在患乳腺癌女性中的联合应用
EP2680839A1 (en) Co -administration of eribulin and farletuzumab for the treatment of breast cancer
JP2021505571A (ja) 末梢t細胞リンパ腫および皮膚t細胞リンパ腫を治療するための組成物および方法
US20240317884A1 (en) Method for allowing immune cells infiltration in tumors
KR20230026493A (ko) Hif-2알파 억제제 및 렌바티닙의 조합물을 사용하여 암 또는 폰-히펠 린다우병을 치료하는 방법
Bryant et al. Repurposed quinacrine synergizes with cisplatin, reducing the effective dose required for treatment of head and neck squamous cell carcinoma
Piha-Paul et al. Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism
JP2021535110A (ja) 併用療法
Casadevall Aguilar et al. mTOR inhibition and T-DM1 in HER2-positive breast cancer
Hernandez-Aya 13 Skin Cancer
US20170333554A1 (en) Dosing regimen
Watanabe et al. 5065 POSTER Trastuzumab Responder Will Show Good Repose to Lapatinib
WARNING PERJETA: for the first-line treatment of HER2+ metastatic breast cancer